Risk factors for secondary glaucoma in children

Article

Risk factors for secondary glaucoma in children

For children with uveitis, juvenile idiopathic arthritis-associated uveitis and ANA-positive uveitis without evidence of arthritis are the most common risk factors for developing secondary glaucoma, according to the results of a study published in the May 2006 issue of Ophthalmology.

Karen M. Sijssens MD, and her colleagues from the FC Donders Institute of Ophthalmology, Utrecht, and the University Eye Clinic, Maastricht, The Netherlands, conducted a retrospective, observational case series of 256 eyes of 147 children diagnosed with uveitis before the age of 16.

The researchers were looking for localization and course of uveitis, underlying systemic disease, onset of ocular hypertension, onset of secondary glaucoma, treatment with steroids, antinuclear antibodies (ANAs), lens extractions, number of blind eyes at onset and during follow-up.

Elevated intraocular pressure (IOP) was recorded in 35% of subjects regardless of the form or type of uveitis. However, secondary glaucoma developed more frequently (38%) in juvenile idiopathic arthritis-associated uveitis compared with other forms of uveitis (11%). Secondary glaucoma was also observed more frequently in subjects who were ANA positive (42%) than those who were ANA negative (6%). Except for patients with juvenile idiopathic arthritis-associated uveitis, periocular steroid injections represented an additional risk factor for secondary glaucoma, limited to the early phases of the disease process.

The results suggest a strong link between juvenile idiopathic arthritis-associated uveitis, ANA-positive uveitis and secondary glaucoma.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.